Effects of 1-year treatment with fluvastatin or pravastatin on bone

被引：47

作者：

Watanabe, S

Fukumoto, S

Takeuchi, Y

Fujita, H

Nakano, T

Fujita, T

机构：

[1] Tokyo Metropolitan Tama Geriatr Hosp, Dept Med, Tokyo, Japan

[2] Tokyo Univ, Branch Hosp, Dept Med & Lab Med, Tokyo 1128688, Japan

来源：

AMERICAN JOURNAL OF MEDICINE | 2001年 / 110卷 / 07期

关键词：

D O I：

10.1016/S0002-9343(01)00679-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：584 / 587

页数：4

共 13 条

[1] Alendronate and estrogen effects in postmenopausal women with low bone mineral density [J].

Bone, HG ;

Greenspan, SL ;

McKeever, C ;

Bell, N ;

Davidson, M ;

Downs, RW ;

Emkey, R ;

Meunier, PJ ;

Miller, SS ;

Mulloy, AL ;

Recker, RR ;

Weiss, SR ;

Heyden, N ;

Musliner, T ;

Suryawanshi, S ;

Yates, AJ ;

Lombardi, A .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (02) :720-726

[2] Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women [J].

Chan, KA ;

Andrade, SE ;

Boles, M ;

Buist, DSM ;

Chase, GA ;

Donahue, JG ;

Goodman, MJ ;

Gurwitz, JH ;

LaCroix, AZ ;

Platt, R .

LANCET, 2000, 355 (9222) :2185-2188

[3] New insights into the pharmacodynamic and pharmacokinetic properties of statins [J].

Corsini, A ;

Bellosta, S ;

Baetta, R ;

Fumagalli, R ;

Paoletti, R ;

Bernini, F .

PHARMACOLOGY & THERAPEUTICS, 1999, 84 (03) :413-428

[4] Oral statins and increased bone-mineral density in postmenopausal women [J].

Edwards, CJ ;

Hart, DJ ;

Spector, TD .

LANCET, 2000, 355 (9222) :2218-2219

[5] Alendronate mechanism of action:: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro [J].

Fisher, JE ;

Rogers, MJ ;

Halasy, JM ;

Luckman, SP ;

Hughes, DE ;

Masarachia, PJ ;

Wesolowski, G ;

Russell, RGG ;

Rodan, GA ;

Reszka, AA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (01) :133-138

[6] Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors [J].

Hamelin, BA ;

Turgeon, J .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (01) :26-37

[7] HMG-CoA reductase inhibitors and the risk of fractures [J].

Meier, CR ;

Schlienger, RG ;

Kraenzlin, ME ;

Schlegel, B ;

Jick, H .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (24) :3205-3210

[8] Physiological regulation of G protein-linked signaling [J].

Morris, AJ ;

Malbon, CC .

PHYSIOLOGICAL REVIEWS, 1999, 79 (04) :1373-1430

[9] Stimulation of bone formation in vitro and in rodents by statins [J].

Mundy, G ;

Garrett, R ;

Harris, S ;

Chan, J ;

Chen, D ;

Rossini, G ;

Boyce, B ;

Zhao, M ;

Gutierrez, G .

SCIENCE, 1999, 286 (5446) :1946-1949

[10] Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets [J].

Osamah, H ;

Mira, R ;

Sorina, S ;

Shlomo, K ;

Michael, A .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (01) :77-83

← 1 2 →